NCT05598606View on ClinicalTrials.gov

Denosumab vs Zoledronate After Vertebroplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

January 10, 2023

Study Completion Date

January 14, 2023

Conditions
Denosumab AllergyZoledronic Acid Allergy
Interventions
DRUG

Denosumab Injection

1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)

DRUG

Zoledronate

Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months

Trial Locations (1)

518000

ShenzhenPH, Shenzhen

All Listed Sponsors
lead

Shenzhen People's Hospital

OTHER

NCT05598606 - Denosumab vs Zoledronate After Vertebroplasty | Biotech Hunter | Biotech Hunter